- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01115959
Seizures Post Intracerebral Hemorrhage
June 11, 2014 updated by: Dr. Yair Lampl, Wolfson Medical Center
Are Post Intracerebal Hemorrhage Prevented By Anti-Epileptic Treatment?
This study examines early antiepileptic treatment with valproic acid for acute cerebral hemorrhage against a placebo group immediately post event to evaluate the outcome of these patients regarding seizures and neurological outcome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- cerebral hemorrhage spontaneous
Exclusion Criteria:
- early seizures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: valproic acid
Valproic acid given orally 400mg twice daily
|
treatment of 1 month dosage of 400 mg BID
|
|
Placebo Comparator: placebo
Placebo twice daily for one month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
number of seizures
Time Frame: study drug for 1 month and 1 year follow up
|
study drug for 1 month and 1 year follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
neurological outcome NIHSS
Time Frame: during 1 month study drug and 1 year post follow up
|
during 1 month study drug and 1 year post follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: ronit gilad, md, E Wolfson med center
- Principal Investigator: ronit gilad, md, E wofson med center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
May 2, 2010
First Submitted That Met QC Criteria
May 2, 2010
First Posted (Estimate)
May 4, 2010
Study Record Updates
Last Update Posted (Estimate)
June 12, 2014
Last Update Submitted That Met QC Criteria
June 11, 2014
Last Verified
May 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Hemorrhages
- Hemorrhage
- Cerebral Hemorrhage
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
Other Study ID Numbers
- 001 (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.